TXG 10x Genomics, Inc.

TXG 10x Genomics, Inc.

Healthcare · Health Information Services

Market read

Scan convergence 1 scan as of 2026-08-17 1 bull converging

POC $12.19 · VWAP $23.58 · +145.9% vs 12m avg buyer

uptrend vol: normalgaps: stablechurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

2 watchlists

TXG Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist TXG belongs to, members best 30-day change first — TXG highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@biotech-capital-cycle
@ibb

Decision history

2 scored calls · newest first · projection

How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.

Jul 2 enter high Margin turn +18.8% complete
Jul 2 pass n/a Watched, not owned +18.8% complete

Desk commentary

Authored analysis and challenge notes tied to TXG.

2

Next earnings TXG reports in 79 days Nov 5

Against street estimates

How TXG's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 10 quarters · newest report Aug 6 · projection Aug 17

Result
Aug 6 -0.020.03+258.4%Beat
May 7 -0.060.07 GAAP ≠ +219.2%Beat
Feb 12 -0.040.07+276.3%Beat
Nov 6 '25 -0.07-0.02 GAAP ≠ +67.4%Beat
Aug 7 '25 -0.080.48 GAAP ≠ +702.1%Beat
May 8 '25 -0.29-0.10 GAAP ≠ +64.9%Beat
Feb 12 '25 -0.11-0.14-27.1%Miss
Oct 29 '24 -0.26-0.02 GAAP ≠ +94.1%Beat